page-template-default,page,page-id-123,bridge-core-2.1.9,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-20.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.1,vc_responsive



Michael Engsig

Chief Executive Officer
Michael Engsig joined Vaccibody in March 2017. He is a broadly anchored pharmaceutical professional with more than 19 years of experience and successful track record in R&D and commercial functions. Michael has a background as Civil Engineer (MSc) in chemistry specialized in biotechnology from the Technical University of Denmark 1998, followed by a Graduate Diploma in Business Administration (HD) – Organization and Leadership from Copenhagen Business School 2001.
Michaels professional experience spans from early stage drug discovery to late stage development and product launches in biotech and pharma and across all major geographical areas.

Agnete B. Fredriksen

President and Chief Scientific Officer
Agnete B. Fredriksen is Co-Founder and joined Vaccibody in 2007. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccine molecules. She received the King’s Gold Medal for her PhD thesis describing Vaccibodies. Her focus is on  cancer vaccines from idea to clinical development. Previous employment includes Affitech AS and Medinnova AS. Agnete is author on numerous scientific papers in the field of immunology, immunotherapy and vaccines. Inventor on several patents in the field of immunotherapy. She is board member for the BIA programme of NRC stimulating research in the Norwegian industry.

Mette Husbyn

Chief Technical Officer
Mette Husbyn joined Vaccibody in October 2017. She holds a PhD in peptide chemistry from University of Oslo, 2003.
Mette has since 1990 worked in CMC drug development throughout all clinical stages from early research to NDA/MAA filings. Mette started her pharmaceutical career in Nycomed Pharma, Oslo as a scientist, followed by assignments within diagnostic imaging in Amersham Health and GE Healthcare, Oslo in various roles (lead scientist, project manager, department manager) over a period of 10 years. Most recently she held the CMC Manager position in Lytix Biopharma, Oslo for over five years, where she was responsible for all CMC related issues, including regulatory within both the antimicrobial and immune oncology programmes.

Siri Torhaug

Chief Medical Officer
Siri Torhaug joined Vaccibody in January 2020 as Chief Medical Officer. She is a medical doctor and certified clinical specialist in Oncology, with broad experience in clinical development and translational research. She has worked with clinical trials from translational research to phase I-IV during her 10 years at Oslo University Hospital, Radiumhospitalet, one of the premier Oncology hospitals in Europe.
Siri has spent the last 7 years working in leading pharmaceutical companies like Novartis and AstraZeneca, within local medical affairs and Nordic medical leadership roles. She has extensive experience in scientific and medical affairs covering relevant tumor areas, R&D and general management of cancer drug development as well as product launches and life cycle management for several oncology products. 

Hans Petter Tjeldflaat

Finance Director
Hans Petter Tjeldflaat joined Vaccibody in October 2012, serving as CFO on a part time basis. He holds ha MSc in Finance from the University of Wisconsin and a Master of General Business from BI.
Hans Petter has since 2003 worked as an independent consultant to life science companies as a part time CFO, hereunder Affitech AS, Inovio AS, Nordic Nanovector AS, Otivio AS, Respinor AS and Nextera AS. Prior to this, Hans Petter held positions as Investment Manager in SND Invest AS and Investor Relations at Christiania Bank.

Karoline W. Schjetne

VP Scientific Affairs
Karoline W. Schjetne joined Vaccibody in August 2017 as Vice President Scientific Affair. She holds a PhD from University of Oslo, followed by a postdoctoral scholarship where she also worked as visiting researcher at Harvard Medical School. Karoline has worked in both biotech and big pharma industry within the area of immunotherapy and inflammatory diseases since 2007. Karoline is author of several scientific papers in this field and her professional experience spans from development and launch of medical devices to market authorization and product launch, lastly as part of medical affairs in Janssen Pharmaceuticals.
Vaccibody juni 19-095

Caspar Foghsgaard

Director Business Development
Caspar Foghsgaard joined Vaccibody in November 2018 as Director Business Development. He holds a MSc in Management from University of Surrey and a Bsc (Hons.) in Chemistry with Biological Chemistry from the University of St Andrews.
Caspar’s professional experience spans from business development and strategy in Novozymes A/S to being an independent consultant to biotech companies. His experience includes diverse transactions within business development, fundraising and mergers & acquisitions.